View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
In patients with chronic obstructive pulmonary disease (COPD) or asthma, a combination of salmeterol and fluticasone propionate (SFC) can cut the risk of dying within 2 years in half, according to a 2-year study. Salmeterol is a long-acting inhaled bronchodilator and fluticasone is an anti-inflammatory drug.
Researchers randomly assigned 1,323 patients with severe COPD to receive either SFC or tiotropium, a long-acting bronchodilator. Tracking exacerbation rate, health status, lung function, mortality, and study withdrawal rate, they found no differences in the rate of exacerbations between the two treatment groups. But patients taking SFC were 50% less likely to die from any cause during the study, and were also less likely to withdraw from the study than patients taking tiotropium.
Patients taking SFC were more likely to require antibiotics to treat exacerbations, while those taking tiotropium were more likely to be treated with oral corticosteroids.
Source: Wedzicha JA, et al., The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide, American Journal of Respiratory and Critical Care Medicine, January 1, 2008.
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top